Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Halozyme Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 390
- +22 vs. Q2 2023
- Shares held
- 123.2M
- −91.1K (−0.1%) vs. Q2 2023
- Total value
- $4.71B
- +$257.9M (+5.8%) vs. Q2 2023
- New holders
- 51
- 134 more added
- Sold out
- 29
- 144 more reduced
2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HALO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 674 | $9.62B |
| Q1 2026 | 637 | $7.79B |
| Q4 2025 | 619 | $8.29B |
| Q3 2025 | 604 | $8.75B |
| Q2 2025 | 552 | $6.05B |
| Q1 2025 | 550 | $7.72B |
| Q4 2024 | 509 | $5.86B |
| Q3 2024 | 510 | $7.17B |
| Q2 2024 | 460 | $6.40B |
| Q1 2024 | 413 | $5.03B |
| Q4 2023 | 411 | $4.62B |
| Q3 2023 | 390 | $4.71B |
| Q2 2023 | 370 | $4.45B |
| Q1 2023 | 387 | $4.77B |
| Q4 2022 | 423 | $7.35B |
| Q3 2022 | 357 | $5.21B |
| Q2 2022 | 368 | $5.65B |
| Q1 2022 | 316 | $5.12B |
| Q4 2021 | 326 | $5.21B |
| Q3 2021 | 326 | $5.29B |
| Q2 2021 | 315 | $5.89B |
| Q1 2021 | 337 | $5.53B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Halozyme Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alberta Investment Management Corp | 0 | $0 | 0.00% | −15,470−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −14,078−100.0% | Sold out |
| Veriti Management LLC | 0 | $0 | 0.00% | −11,371−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −11,087−100.0% | Sold out |
| CSS LLC | 0 | $0 | 0.00% | −10,700−100.0% | Sold out |
| Must Asset Management Inc. | 0 | $0 | 0.00% | −6,198−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −5,902−100.0% | Sold out |
| DuPont Capital Management Corp | 0 | $0 | 0.00% | −2,202−100.0% | Sold out |
| Harbor Investment Advisory, LLC | 0 | $0 | 0.00% | −1,869−100.0% | Sold out |
| Cullen/Frost Bankers, Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| West Tower Group, LLC | 0 | $0 | 0.00% | −766−100.0% | Sold out |
| Brown Brothers Harriman & Co | 0 | $0 | 0.00% | −381−100.0% | Sold out |
| Horan Securities, Inc. | 0 | $0 | 0.00% | −266−100.0% | Sold out |
| PEAK6 Investments LLC | 0 | $0 | 0.00% | −266−100.0% | Sold out |
| Elequin Capital LP | 0 | $0 | 0.00% | −190−100.0% | Sold out |
| NewSquare Capital LLC | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Cornerstone Planning Group LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Disciplined Investments, LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Pictet Asset Management SA | – | – | – | – | Not filed |
| Efg Capital International Corp. | – | – | – | – | Not filed |